Importantly, treatment of lung cancer cells harboring KRAS mutations with the mTORC1 inhibitor rapamycin restored chemosensitivity of the resistant cells and, combination of rapamycin and chemotherapy showed strong synergistic effect in inhibiting tumor growth [42]. Here, KRAS is linked to lung carcinoma.